Background <p>The discovery and therapeutic application of immune checkpoint inhibitors (ICIs) have significantly improved clinical outcomes in cancer treatment. However, the response rate is still low in gastrointestinal (GI) cancers. The gut microbiome’s impact on immune modulation is a promising area for overcoming resistance to immunotherapy.</p> Methods <p>This study (NCT04130763) is an open-label, single-arm, single-center, phase I study assessing the…
Fecal microbiota transplantation combined with anti-PD-1 therapy in refractory microsatellite-stable gastric cancer: a phase I feasibility and safety study
Journal for ImmunoTherapy of Cancer | | Zhang, Y., Xu, X., Wang, S., Yin, X., Zhang, B., Zhu, Z., Ji, R., Zhu, J., He, H., Cheng, S., Han, Z., Xie, T., Zhang, X., Wang, Y., Shen, S., Kou, Y., Bao, S., Liu, Y., Cao, B., Bonny, C., Guo, X., Segal, E., Tan, Y., Shen, L., Peng, Z.
Topics: stomach-cancer, immunotherapy, clinical-trials, research
Read the full article at Journal for ImmunoTherapy of Cancer